Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 7/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 7/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 7/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 7/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 7/20 | 0.51 |
| ▸ | MDH2 | P40926 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810852 | 0.82 | PRKAB2 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL5191098 | 0.81 | HTT (0.42) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL6276116 | 0.77 | CSNK2A2 (0.40) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4963341 | 0.74 | HTT (0.46) | MDH2HTTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3812486 | 0.73 | GABRA1 (0.53) | HTT | |
| SCHEMBL3810534 | 0.73 | KDM4E (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL13799059 | 0.73 | KDM4E (0.43) | HTTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL335129 | 0.73 | KDM4E (0.43) | HTTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5163027 | 0.72 | HTT (0.49) | MDH2HTTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4960099 | 0.72 | HTT (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| EP-1756135-A1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005108412-A1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | CYP51A1, TLR5, MALT1 | PRKAB2 4289/4885PRKAG1 4275/4885PRKAA2 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.